secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001140361-22-040374
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q3 revenue $2.1M (+11% YoY); net loss narrows to $3.9M
---------------------------------------------------------------

- Revenue $2.1M, up 11% from Q3 2021; gross margin 61% vs. 60.4%.
- Net loss $3.9M ($0.37 loss/share) vs. $5.3M ($0.75 loss/share) a year ago.
- SG&A expenses $4.3M vs. $4.6M; R&D expenses $0.9M vs. $1.7M.
- Cash $12.1M at Sep 30; closed $11M public offering on Oct 18, pro-forma cash ~$21.9M.
- Activated 3 sites for REVERSE-HF study; awarded U.S. patent for pediatric dialysis innovation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036122040374/0001140361-22-040374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036122040374/brhc10043820_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer